628 related articles for article (PubMed ID: 34083781)
1. Interleukins in cancer: from biology to therapy.
Briukhovetska D; Dörr J; Endres S; Libby P; Dinarello CA; Kobold S
Nat Rev Cancer; 2021 Aug; 21(8):481-499. PubMed ID: 34083781
[TBL] [Abstract][Full Text] [Related]
2. Mutations and regulatory anomalies effecting tumor cell immune functions.
Blanck G
Cancer Immunol Immunother; 2004 Jan; 53(1):1-16. PubMed ID: 13680191
[TBL] [Abstract][Full Text] [Related]
3. Harnessing cytokines and chemokines for cancer therapy.
Propper DJ; Balkwill FR
Nat Rev Clin Oncol; 2022 Apr; 19(4):237-253. PubMed ID: 34997230
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem cell-immune cell crosstalk in tumour progression.
Bayik D; Lathia JD
Nat Rev Cancer; 2021 Aug; 21(8):526-536. PubMed ID: 34103704
[TBL] [Abstract][Full Text] [Related]
5. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors.
Cadilha BL; Benmebarek MR; Dorman K; Oner A; Lorenzini T; Obeck H; Vänttinen M; Di Pilato M; Pruessmann JN; Stoiber S; Huynh D; Märkl F; Seifert M; Manske K; Suarez-Gosalvez J; Zeng Y; Lesch S; Karches CH; Heise C; Gottschlich A; Thomas M; Marr C; Zhang J; Pandey D; Feuchtinger T; Subklewe M; Mempel TR; Endres S; Kobold S
Sci Adv; 2021 Jun; 7(24):. PubMed ID: 34108220
[TBL] [Abstract][Full Text] [Related]
6. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8
Xu S; Chaudhary O; Rodríguez-Morales P; Sun X; Chen D; Zappasodi R; Xu Z; Pinto AFM; Williams A; Schulze I; Farsakoglu Y; Varanasi SK; Low JS; Tang W; Wang H; McDonald B; Tripple V; Downes M; Evans RM; Abumrad NA; Merghoub T; Wolchok JD; Shokhirev MN; Ho PC; Witztum JL; Emu B; Cui G; Kaech SM
Immunity; 2021 Jul; 54(7):1561-1577.e7. PubMed ID: 34102100
[TBL] [Abstract][Full Text] [Related]
7. SETDB1, a new target for immunotherapy.
Harjes U
Nat Rev Cancer; 2021 Jul; 21(7):412. PubMed ID: 34083782
[No Abstract] [Full Text] [Related]
8. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation.
Dixon KO; Tabaka M; Schramm MA; Xiao S; Tang R; Dionne D; Anderson AC; Rozenblatt-Rosen O; Regev A; Kuchroo VK
Nature; 2021 Jul; 595(7865):101-106. PubMed ID: 34108686
[TBL] [Abstract][Full Text] [Related]
9. The immunological and metabolic landscape in primary and metastatic liver cancer.
Li X; Ramadori P; Pfister D; Seehawer M; Zender L; Heikenwalder M
Nat Rev Cancer; 2021 Sep; 21(9):541-557. PubMed ID: 34326518
[TBL] [Abstract][Full Text] [Related]
10. CD8
Philip M; Schietinger A
Nat Rev Immunol; 2022 Apr; 22(4):209-223. PubMed ID: 34253904
[TBL] [Abstract][Full Text] [Related]
11. Advancing targeted protein degradation for cancer therapy.
Dale B; Cheng M; Park KS; Kaniskan HÜ; Xiong Y; Jin J
Nat Rev Cancer; 2021 Oct; 21(10):638-654. PubMed ID: 34131295
[TBL] [Abstract][Full Text] [Related]
12. Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade.
Berry S; Giraldo NA; Green BF; Cottrell TR; Stein JE; Engle EL; Xu H; Ogurtsova A; Roberts C; Wang D; Nguyen P; Zhu Q; Soto-Diaz S; Loyola J; Sander IB; Wong PF; Jessel S; Doyle J; Signer D; Wilton R; Roskes JS; Eminizer M; Park S; Sunshine JC; Jaffee EM; Baras A; De Marzo AM; Topalian SL; Kluger H; Cope L; Lipson EJ; Danilova L; Anders RA; Rimm DL; Pardoll DM; Szalay AS; Taube JM
Science; 2021 Jun; 372(6547):. PubMed ID: 34112666
[TBL] [Abstract][Full Text] [Related]
13. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma.
Jacquelot N; Seillet C; Wang M; Pizzolla A; Liao Y; Hediyeh-Zadeh S; Grisaru-Tal S; Louis C; Huang Q; Schreuder J; Souza-Fonseca-Guimaraes F; de Graaf CA; Thia K; Macdonald S; Camilleri M; Luong K; Zhang S; Chopin M; Molden-Hauer T; Nutt SL; Umansky V; Ciric B; Groom JR; Foster PS; Hansbro PM; McKenzie ANJ; Gray DHD; Behren A; Cebon J; Vivier E; Wicks IP; Trapani JA; Munitz A; Davis MJ; Shi W; Neeson PJ; Belz GT
Nat Immunol; 2021 Jul; 22(7):851-864. PubMed ID: 34099918
[TBL] [Abstract][Full Text] [Related]
14. Non-coding driver mutations in human cancer.
Elliott K; Larsson E
Nat Rev Cancer; 2021 Aug; 21(8):500-509. PubMed ID: 34230647
[TBL] [Abstract][Full Text] [Related]
15. MYC protein interactors in gene transcription and cancer.
Lourenco C; Resetca D; Redel C; Lin P; MacDonald AS; Ciaccio R; Kenney TMG; Wei Y; Andrews DW; Sunnerhagen M; Arrowsmith CH; Raught B; Penn LZ
Nat Rev Cancer; 2021 Sep; 21(9):579-591. PubMed ID: 34188192
[TBL] [Abstract][Full Text] [Related]
16. Innate immune cells in the tumor microenvironment.
Li MO; Wolf N; Raulet DH; Akkari L; Pittet MJ; Rodriguez PC; Kaplan RN; Munitz A; Zhang Z; Cheng S; Bhardwaj N
Cancer Cell; 2021 Jun; 39(6):725-729. PubMed ID: 34129817
[TBL] [Abstract][Full Text] [Related]
17. Tim-4
Chow A; Schad S; Green MD; Hellmann MD; Allaj V; Ceglia N; Zago G; Shah NS; Sharma SK; Mattar M; Chan J; Rizvi H; Zhong H; Liu C; Bykov Y; Zamarin D; Shi H; Budhu S; Wohlhieter C; Uddin F; Gupta A; Khodos I; Waninger JJ; Qin A; Markowitz GJ; Mittal V; Balachandran V; Durham JN; Le DT; Zou W; Shah SP; McPherson A; Panageas K; Lewis JS; Perry JSA; de Stanchina E; Sen T; Poirier JT; Wolchok JD; Rudin CM; Merghoub T
Cancer Cell; 2021 Jul; 39(7):973-988.e9. PubMed ID: 34115989
[TBL] [Abstract][Full Text] [Related]
18. The role of T cells in age-related diseases.
Carrasco E; Gómez de Las Heras MM; Gabandé-Rodríguez E; Desdín-Micó G; Aranda JF; Mittelbrunn M
Nat Rev Immunol; 2022 Feb; 22(2):97-111. PubMed ID: 34099898
[TBL] [Abstract][Full Text] [Related]
19. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma.
Hara T; Chanoch-Myers R; Mathewson ND; Myskiw C; Atta L; Bussema L; Eichhorn SW; Greenwald AC; Kinker GS; Rodman C; Gonzalez Castro LN; Wakimoto H; Rozenblatt-Rosen O; Zhuang X; Fan J; Hunter T; Verma IM; Wucherpfennig KW; Regev A; Suvà ML; Tirosh I
Cancer Cell; 2021 Jun; 39(6):779-792.e11. PubMed ID: 34087162
[TBL] [Abstract][Full Text] [Related]
20. T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.
Briukhovetska D; Suarez-Gosalvez J; Voigt C; Markota A; Giannou AD; Schübel M; Jobst J; Zhang T; Dörr J; Märkl F; Majed L; Müller PJ; May P; Gottschlich A; Tokarew N; Lücke J; Oner A; Schwerdtfeger M; Andreu-Sanz D; Grünmeier R; Seifert M; Michaelides S; Hristov M; König LM; Cadilha BL; Mikhaylov O; Anders HJ; Rothenfusser S; Flavell RA; Cerezo-Wallis D; Tejedo C; Soengas MS; Bald T; Huber S; Endres S; Kobold S
Immunity; 2023 Jan; 56(1):143-161.e11. PubMed ID: 36630913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
